SHR 2024 Abstract Submissions

Please Note: The abstract submission period has ended.

Submit an abstract for presentation at SHR 2024! The goal of SHR 2024 is to present and discuss advances in steroid hormone action in biology and medicine, exploring their role in biology, chemistry, pharmacology, oncology, neurology, metabolism, cardiovascular biology and endocrinology. The conference will feature Plenary and Keynote Lectures, oral presentations and posters by prominent and emerging leaders as well as trainees in the field. Conference proceedings will be published in an international peer-reviewed journal. Sessions will cover (but are not limited to) the following topics:

• Cancer Biology and Therapeutics
• Cardiovascular Biology and Disease
• Neurobiology and Aging
• Metabolism and Comorbidities
• Molecular and Structural Biology of Steroid Receptors
• Immune System and Inflammation
• Systems Biology and Cell Signaling Networks

Abstract Submissions closed on September 13, 2024.

Submission Requirements:

• All abstracts must be submitted via the online submission site. Submissions will not be accepted via other means, i.e., email, fax, postal mail, etc.
• Upon submission, the presenting author of the abstract agrees to register and attend the Steroid Hormone and Receptors (SHR) 2024 conference to present the abstract. If the presenter is unable to attend, a co-author may register for the conference and present in their place. If the presenting author or appropriate co-author fails to register and present the abstract at the SHR conference, the submission will be considered withdrawn from this event.
• The abstract character limit is 2,500 characters, including punctuation and symbols, but not spaces.
• Endocrine Society membership is not a requirement to submit an abstract for the SHR 2024 conference. Membership status has no impact on peer review decisions if accepted for presentation.
• Endocrine Society members receive special discounted registration rates. Join now to get the best registration rates.
• Abstracts must have a submission status of COMPLETE by the submission deadline. An abstract is not considered complete until all required information has been submitted. Requests to submit abstracts beyond the stated deadline will not be considered.
• Abstracts must be submitted in English.

Report original information.

At the time of submission, the study/clinical case report should contain unpublished information. The abstract should not include any previously published verbatim information/text as a scientific article or meeting abstract. The abstract submitted for SHR 2024 must contain novel and original scientific data and information to reflect ongoing progress.

The submission must fit into at least one of the provided abstract categories. The Endocrine Society welcomes industry submissions containing endocrine research, scientific data, and results. Abstracts deemed to contain commercial content, commercial products, or service-related advertisements or opinions lacking rigorous scientific data may be rejected.

Disclose any and all real or perceived financial relationships.

In general, disclosure is required when an individual or company stands to benefit financially from research performed. The central criterion of this policy places the onus for disclosure on each author to indicate any benefit to an individual or company that may derive from any and all relationships that have the potential to lead to financial gain. Any potential for financial gain derived from reported work might constitute a conflict of interest. Authors should clearly acknowledge financial contributions from commercial sponsors to the work being reported, which might be perceived as conflicts of interest (see III.2). Authors should ensure that no contractual relations or proprietary considerations restrict dissemination of their findings. It is the author's responsibility to report any real or perceived financial relationships. Relevant financial relationships are noted next to the published abstract directing readers to relevant financial relationships listed in the Program.

Please Note: The abstract submission period has ended.